Scientists are studying brain scans and biological markers trying to figure out in advance which patients will respond best to psychedelic therapy — the same way a blood test can predict how someone will respond to certain cancer drugs. Despite lots of promising research, nobody will have a test that's actually validated and ready for real clinical use by the end of 2027. This matters because without such a test, doctors can't reliably match patients to treatments.
Mechanistic publications on plasticity and connectivity continue to grow, but translating these into a prospectively validated, clinically deployable biomarker requires large confirmatory datasets that are not yet underway. Reframed from a vague 'outpace' claim into a binary, checkable absence-of-validated-biomarker statement.